International Journal of Hematology

, Volume 92, Issue 3, pp 518–523

Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience

  • Natsue Igarashi
  • Takaaki Chou
  • Takayuki Hirose
  • Yousuke Imai
  • Takuro Ishiguro
Original Article

DOI: 10.1007/s12185-010-0690-x

Cite this article as:
Igarashi, N., Chou, T., Hirose, T. et al. Int J Hematol (2010) 92: 518. doi:10.1007/s12185-010-0690-x

Abstract

Bortezomib is a novel proteasome inhibitor, which has shown high antimyeloma activity. APEX trial, phase III randomized study for relapsed or refractory myeloma established efficacy and feasibility of bortezomib. In our study, we retrospectively investigated 60 Japanese patients with relapsed or refractory multiple myeloma (MM) who underwent bortezomib and dexamethasone (BD) therapy in our institution. Overall response rate was 75%, including 7 cases (11.7%) of complete response and 13 cases (21.7%) of very good partial response. Stable disease and progressive disease were observed in 15 patients (25%). Major ≥grade 3 adverse events were hematological toxicities and grade 3 non-hematological toxicities included appetite loss, diarrhea and peripheral neuropathy. BD therapy was well tolerated, and produced significant response in relapsed or refractory MM patients. Recently, many worldwide trials including bortezomib or other new agents are ongoing to evaluate its efficacy not only as a therapy for relapsed or refractory disease but also as a frontline therapy. Further investigations are required to define how to use new antimyeloma agents for Japanese MM patients.

Keywords

BortezomibMultiple myelomaPlateau phaseAutologous stem cell transplantationHigh-dose chemotherapy

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  • Natsue Igarashi
    • 1
  • Takaaki Chou
    • 1
  • Takayuki Hirose
    • 1
  • Yousuke Imai
    • 1
  • Takuro Ishiguro
    • 1
  1. 1.Department of Internal MedicineNiigata Cancer Center HospitalNiigata CityJapan